1. Department of Hematology, Graduate School of Medical Sciences, International University of Health and Welfare Hospital, Tochigi, Japan;
2. Blood Transfusion Service, Mie University Hospital, Mie, Japan;
3. Division of Hematology, Department of Medicine, Keio University Hospital, Tokyo, Japan;
4. Department of Hematology/Oncology, University of Yamanashi, Yamanashi, Japan;
5. Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan;
6. Department of Hematology, Tokyo Medical University, Tokyo, Japan;
7. Department of Medicine, Gunma University Hospital, Gunma, Japan;
8. Department of Hematology, Nagoya University Hospital, Nagoya, Japan;
9. Department of Hematology and Oncology, JRC Nagoya Daini Red Cross Hospital, Aichi, Japan;
10. Center for Cellular and Molecular Medicine, Kyushu University Hospital, Japan;
11. Gastroenterology and Hematology, University of Miyazaki, Miyazaki, Japan;
12. Department of Medical Affairs–Oncology, Novartis Pharma KK, Tokyo, Japan;
13. Clinical Development, Japan Integrated Biostatistics, Novartis Pharma KK, Tokyo, Japan;
14. Department of Commercial Excellence–Oncology, Novartis Pharma KK, Tokyo, Japan;
15. Department of Biomedical Sciences, Ritsumeikan University, Shiga, Japan;
16. Department of Medicine and Biosystemic Sciences, Kyushu University, Fukuoka, Japan